Abstract: The use of substituted 3,4-dihydro-2H-benzopyrans as remedies for obstructive functional disorders of the lungs and/or disorders of the efferent urinary passagesThe use of 3,4-dihydro-2H-benzo[b]pyrans of the formula I ##STR1## in which R.sup.1 represents H, OH, (C.sub.1 -C.sub.2)-alkoxy, (C.sub.1 -C.sub.2)-alkyl or NR.sup.4 R.sup.5, where R.sup.4 and R.sup.5 are identical or different and represent H, (C.sub.1 -C.sub.2)-alkyl or (C.sub.1 -C.sub.3)-alkyl-carbonyl,R.sup.2 and R.sup.3 are identical or different and represent alkyl having 1-4 carbon atoms,Ar represents an aromatic or heteroaromatic system which is unsubstituted or substituted by 1 to 3 identical or different radicals (C.sub.1 -C.sub.2)-alkyl, (C.sub.1 -C.sub.2)-alkoxy, halogen, trifluoromethyl, CN, NO.sub.2, CO--(C.sub.1 -C.sub.2)-alkyl or SO.sub.m --(C.sub.1 -C.sub.2)-alkyl with m=1 or 2,n represents 1 or 2,X represents a chain (CH.sub.2).sub.r which can be interrupted by a heteroatom O, S or NR.sup.6, where R.sup.6 denotes H or (C.sub.1 -C.

Abstract: Benzoylguanidines of the formula I ##STR1## where R(1) or R(2) is equal to R(6)--S(O).sub.n -- or R(7)R(8)N--O.sub.2 S--and the other substituent R(1) or R(2) is in each case equal to H, F, Cl, Br, I, alkyl, alkoxy or phenoxy, R(6)--S(O).sub.n or R(7)R(8)N--and R(6) is equal to alkyl, cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl,R(7) and R(8) are equal to alkyl or phenylalkyl or phenyl,and in which R(7) and R(8) may also together be a C.sub.4 --C.sub.7 chain, and in which R(7) and R(8), together with the nitrogen atom to which they are bonded, may be a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system,and where R(3), R(4) and R(5) are equal to hydrogen or alkyl, or R(3) and R(4) are together an alkylene chain or R(4) and R(4) are together an alkylene chain,and where n is equal to zero, 1 or 2and their pharmaceutically tolerable salts are outstanding antiarrhythmics.

Abstract: 2,3,4,5-Tetrahydro-1-benzoxepins of the formula I ##STR1## with R.sup.1 equaling, inter alia, H, alkyl, alkoxy, Hal, alkylsulfonyl, arylsulfonyl, R.sup.2 equaling H, alkyl, alkoxy, OH, R.sup.3 to R.sup.6 H or alkyl and X equaling ##STR2## have excellent efficacy as antihypertensives, as coronary therapeutics, as agents for the treatment of cardiac insufficiency, of disturbances of cerebral and peripheral blood flow or of disturbances of intestinal motility, premature labor, obstructions of the airways or of the urinary tract or of the biliary tract or as spasmolytics.

Abstract: Naphthylalkylamino-substituted sulfamoylbenzoic acid derivatives, processes for the preparation thereof and the use thereof as medicines.Compounds I ##STR1## R(1) hydrogen, (C.sub.1 -C.sub.4)-alkyl and Na, K, NH.sub.4, Ca, Mg, R(2) and R(3) hydrogen, alkyl groups which can also be linked together in a ring,X oxygen, sulfur, SO, SO.sub.2, NR(6) [with R(6)=hydrogen-alkyl], CH.sub.2, CO, or a bond,R(4) phenyl, thienyl, which are unsubstituted or substitutedR(5) hydrogen, (C.sub.1 -C.sub.4)-alkyl,n 1, 2, 3 or 4,where the naphthyl system is unsubstituted or substituted like the phenyl radical of R(4),and where X and R(4) together can also be Cl are medicaments for treating sickle-cell anemia.

Abstract: Benzo[b]pyran derivatives of the formula I ##STR1## with E--D equal to CH--CHOH or C.dbd.CH;X equal to oxygen or sulfur;Y equal to oxygen, sulfur, SO, SO.sub.2 or NR.sup.9 ;R.sup.1 equal to CN, NO.sub.2, Hal, alkoxycarbonyl, SO.sub.1-2 -alkyl or SO.sub.1-2 -aryl;R.sup.2 equal to H, OH, alkoxy, alkyl, Hal, NR.sup.10 R.sup.11 ;R.sup.3 /R.sup.4 equal to alkyl;R.sup.5 /R.sup.6 equal to alkyl, (CH.sub.2).sub.1-6 COO-alkyl, (CH.sub.2).sub.1-6 CONR.sup.10 R.sup.11, (CH.sub.2).sub.0-6 COOH, (CH.sub.2).sub.1-6 CO-alkyl, CO.sub.2 -alkyl, alkylmercaptoalkyl, alkylsulfi(i)(o)nyl, hydroxyalkyl, mercaptoalkyl, aminoalkyl, N-(di)-alkylaminoalkyl or (CH.sub.2).sub.f Ar with f equal to zero-3;R.sup.7 /R.sup.8 equal to hydrogen, alkyl or phenyl, and m equal to zero-2are outstanding antihypertensives and spasmolytics. Preparation processes and use are described.

Abstract: Benzoylguanidines of the formula I ##STR1## where R(1) or R(2) is equal to R(6)--S(O).sub.n -- or R(7)R(8)N--O.sub.2 S--and the other substituent R(1) or R(2) is in each case equal to H, F, Cl, Br, I, alkyl, alkoxy or phenoxy, R(6)--S(O).sub.n or R(7)R(8)N--and R(6) is equal to alkyl, cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl,R(7) and R(8) are equal to alkyl or phenylakyl or phenyl,and in which R(7) and R(8) may also together be a C.sub.4 -C.sub.7 chain, and in which R(7) and R(8), together with the nitrogen atom to which they are bonded, may be dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system,and where R(3), R(4) and R(5) are equal to hydrogen or alkyl, or R(3) and R(4) are together an alkylene chain or R(4) and R(5) are together an alkylene chain,and where n is equal to zero, 1 or 2 and their pharmaceutically tolerable salts are outstanding antiarrhythmics.

Abstract: Compounds I ##STR1## where R.sup.1 is H, alkyl, alkoxy, CO alkyl, COOH, carboxyalkyl, CONR.sub.2, CN, NO.sub.2, alkylsulfi(o)nyl, arylsulfi(i)-nyl; R.sup.2 is H, OH, alkoxy, alkyl or alkylcarbonyl, R.sup.3 /R.sup.4 are alkyl, m is zero or one and X is --CR.sup.6 .dbd.CR.sup.7 -(--CR.sup.8 .dbd.CR.sup.9) (R.sup.6 R.sup.9 are H or alkyl), where n is zero or 1, are described. They are active antihypertensives and spasmolytics for the bladder, intestine, gall bladder, uterus, trachea and ureter.

Abstract: 3,4-Dihydro-2H-benzo[b]pyrans of the formula I ##STR1## are described, in which R.sup.1 is H, OH, (C.sub.1 -C.sub.2)-alkoxy, (C.sub.1 -C.sub.2)-alkyl or NR.sup.4 R.sup.5,R.sup.4 and R.sup.5 being identical or different and representing H, (C.sub.1 -C.sub.2)-alkyl or (C.sub.1 -C.sub.3)-alkylcarbonyl,R.sup.2 and R.sup.3 are identical or different and are alkyl having 1-4 carbon atoms,Ar is an aromatic or heteroaromatic system which is unsubstituted or substituted,n is 1 or 2 andX is a (CH.sub.2).sub.r chain which can be interrupted by a heteroatom O, S or NR.sup.6, R.sup.6 being H or (C.sub.1 -C.sub.4)-alkyl andr being one of the numbers 2, 3, 4 or 5.Processes for the preparation of these compounds, their use and pharmaceutical products based on these compounds are also described.

Abstract: Compounds I ##STR1## with R equal to hydrogen or (C.sub.1 -C.sub.4)-alkyl,X equal to (CH.sub.2).sub.n with n=1-4, unsubstituted or substituted, andAr is equal to an aromatic or heteroaromatic system, optionally substituted,and their pharmaceutically tolerated salts are valuable pharmaceuticals for the treatment of cerebral edema or diarrhea.

Abstract: Combination of angiotensin converting enzyme inhibitors with potassium channel modulators and use thereof in pharmaceuticals.The invention relates to combinations of angiotensin converting enzyme inhibitors with potassium channel modulators, processes for their preparation and use thereof as medicaments.

Abstract: A description is given of a process for the preparation of a compound of the formula I ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 (identical or different) represent H, alkyl having 1-2 carbon atoms and F, Cl, Br or I;R.sup.4 represents H, alkyl having 1-4 carbon atoms, n represents the numbers 2-5, andR.sup.5 represents a radical which can be eliminated under physiological conditions or represents hydrogen, and its physiologically tolerated salts.They are effective remedies for diarrhea.

Abstract: A description is given of the use of amino-substituted benzoic acid derivatives of the formula I ##STR1## in which R.sup.1 and R.sup.2 denote hydrogen, (cyclo)alkyl, unsubstituted or substituted phenyl or naphthyl, or R.sup.1 and R.sup.2 together denote a chain --(CH.sub.2).sub.m -- with m=3 to 6, or together denote a chain --(CH.dbd.CH).sub.n -- with n equal to 2 or 3; R.sup.3 denotes hydrogen, halogen or alkyl; R.sup.4 denotes hydrogen or NO.sub.2 ; R.sup.5 denotes hydrogen or a radical which can be eliminated under physiological conditions; for the preparation of a remedy for diarrhea.

Abstract: The invention relates to 2-aminomethylphenols of the formula I ##STR1## in which R.sup.1 and R.sup.2 represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or benzyl which is optionally substituted by alkyl, alkoxy or halogen, R.sup.3 and R.sup.5 denote hydrogen, halogen, alkyl or alkoxy, R.sup.4 denotes halogen, alkyl or cycloalkyl and R.sup.6 and R.sup.7 represent hydrogen or alkyl, it being possible for the radicals R.sup.1 and R.sup.2, R.sup.6 R.sup.7 and/or two of the radicals R.sup.3, R.sup.4 and R.sup.5 to form an alkylene chain which is optionally substituted by methyl groups and which, in the case of the radicals R.sup.1, R.sup.2, R.sup.6 and R.sup.7, can also be interrupted by oxygen atoms, sulfur atoms and/or imino groups, and to physiologically acceptable salts thereof, a process for their preparation, and their use and to pharmaceutical formulations based on these compounds.

Abstract: Compounds of the formula I ##STR1## where R.sup.1 is hydrogen, lower alkyl, lower alkoxy, amino or dialkylamino; R.sup.2 and R.sup.3 are O-alkyl, N-dialkyl or S-alkyl, or R.sup.2 and R.sup.3 together represent --X--(CH.sub.2).sub.m --X, a carbonyl group or an imino group NR, and m is 2-6; where R.sup.4 is lower alkyl, cycloalkyl, alkenyl or dialkylamino, and where R.sup.5 is lower alkyl or cycloalkyl, and where n is 1 or 2, have excellent cytoprotective effects.They are prepared by reacting compounds II ##STR2## with formaldehyde or a reagent producing formaldehyde.

Abstract: The invention relates to 2-aminomethylphenols of the formula I ##STR1## in which R.sup.1 and R.sup.2 represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or benzyl which is optionally substituted by alkyl, alkoxy or halogen, R.sup.3 and R.sup.5 denote hydrogen, halogen, alkyl or alkoxy, R.sup.4 denotes halogen, alkyl or cycloalkyl and R.sup.6 and R.sup.7 represents hydrogen or alkyl, it being possible for the radicals R.sup.1 and R.sup.2, R.sup.6 and R.sup.7 and/or two of the radicals R.sup.3, R.sup.4 and R.sup.5 to form an alkylene chain which is optionally substituted by methyl groups and which, in the case of the radicals R.sup.1, R.sup.2, R.sup.6 and R.sup.7, can also be interrupted by oxygen atoms, sulfur atoms and/or imino groups, and to physiologically acceptable salts thereof, a process for their preparation, and their use and to pharmaceutical formulations based on these compounds.